CD47 and melanoma: It remains to be seen whether this combination will prove effective for melanoma in vivo; however, other solid tumor models have demonstrated success with pairing αCD47 strategies with CAR-Ms both in vitro and in vivo [12, 24, 25, 64], although more work is required to determine the safest approach to inhibit CD47/SIRPα signaling in the clinic.